Currently, despite the well-known molecular heterogeneity of breast cancer and the discovery of significant mutations that distinguish various subtypes, the hormone receptors ER, PR, and HER2 are the only clinically relevant biomarkers and proven therapeutic targets. Here, NR4A1 is linked to breast cancer.